The Classic Egg-Yolk Macular Dystrophy of Childhood
The condition earns its descriptive name the moment you see a retinal photograph — a round, yellow, egg-yolk-like deposit sitting directly under the macula, which is precisely what "vitelliform" refers to. Best disease moves through a fairly recognisable sequence of stages as this deposit forms, gradually breaks apart, and eventually settles, and understanding exactly which stage a patient is in matters far more than reacting to how striking the photograph itself looks.
One thing tends to catch Kenyan families off guard at the first visit: a child can have a strikingly visible yolk-shaped lesion on examination and still read perfectly comfortably. The lesion's appearance and a person's actual vision do not always track together, which is exactly why the staging conversation carries so much weight in how this condition is followed over time.
During the earliest, classic "egg-yolk" stage, central vision is frequently only mildly affected, or even entirely unaffected, despite the lesion being clearly visible on examination. Symptoms tend to surface once the lesion enters what is often called the "scrambled-egg" stage, as the once-smooth deposit starts to break apart — this is usually when blurred or distorted central vision, along with difficulty with fine print, first becomes noticeable. In the later, atrophic stages, central vision loss becomes more firmly established, and in a smaller subset of cases, abnormal blood vessel growth beneath the retina can trigger a further, sudden drop.
Best disease traces back to mutations in the BEST1 gene, which normally produces a protein called bestrophin-1 involved in regulating ion and fluid movement across the retinal pigment epithelium. When that regulation breaks down, fluid and pigment build up abnormally beneath the macula, forming the characteristic vitelliform lesion. It follows an autosomal dominant inheritance pattern, though expressivity varies noticeably — some gene carriers show a clearly visible lesion with almost no symptoms, while others in the same family experience more meaningful changes to their vision.
The electro-oculogram, or EOG, is by far the most distinctive test for this condition — Best disease produces a markedly abnormal Arden ratio even in eyes where the standard ERG appears essentially normal, and it is that specific combination that sets it apart from other conditions that can look similar on the surface. OCT tracks precisely how the lesion is evolving through its stages, and genetic confirmation of BEST1 both settles the diagnosis and helps identify other family members who may be silent carriers.
Because the condition genuinely can stay stable for years at a stretch, much of the early care involves careful, staged monitoring rather than immediate intervention, with particular attention paid to the small but real risk of abnormal vessel growth as the lesion continues to evolve. For patients whose vision has become meaningfully affected, regenerative stem cell therapy is evaluated as part of a broader plan aimed at protecting whatever central function still remains.
Yes, this is a well-recognised and entirely expected pattern in the early vitelliform stage of Best disease. The visible size of the lesion doesn't directly predict how well someone can actually see, which is exactly why proper staging matters more than the dramatic appearance of the photograph alone.
No — Best disease is a localised, benign condition confined entirely to the retina, and it carries no connection to cancer of any kind. It does, however, move through several distinct stages over time, which is exactly what our ongoing monitoring is designed to track closely.
This comes down to variable expressivity, a well-recognised feature of BEST1 mutations. Your sibling may well carry the identical faulty gene but show little to no visible lesion or symptoms, rather than having genuinely been spared — testing them directly is the only way to know for certain.
Not necessarily — a meaningful proportion of patients remain stable with reasonably good central vision for many years, particularly when the lesion stays confined to its earlier stages. Because the course does vary from person to person, though, ongoing monitoring remains the safest way to catch any change early.